Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF): 2021-2024

Historic Depreciation & Amortization (CF) for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $900,000.

  • Amylyx Pharmaceuticals' Depreciation & Amortization (CF) fell 50.00% to $100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $600,000, marking a year-over-year decrease of 40.06%. This contributed to the annual value of $900,000 for FY2024, which is 18.18% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Depreciation & Amortization (CF) of $900,000 as of FY2024, which was down 18.18% from $1.1 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $1.1 million in FY2023 and a low of $52,000 during FY2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $900,000 (2024), whereas its average is $829,000.
  • In the last 5 years, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) spiked by 836.54% in 2022 and then decreased by 18.18% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $52,000 in 2021, then skyrocketed by 836.54% to $487,000 in 2022, then soared by 125.87% to $1.1 million in 2023, then decreased by 18.18% to $900,000 in 2024.